Intra-Abdominal Infections

12345678910
Across
  1. 3. Complicated intra-abdominal infections are often caused by gram ___ and anaerobic pathogens.
  2. 5. One common adverse reaction of Emblaveo.
  3. 6. One challenge of treating complicated intra-abdominal infections is the creation of ___ by bacteria, which involve a matrix that is difficult for antibiotics to penetrate.
  4. 9. The infusion time of Emblaveo is ___ hours.
  5. 10. Emblaveo was FDA-approved to use in combination with ___ to treat complicated intra-abdominal infections.
Down
  1. 1. Emblaveo is a combination antibiotic made of ___ and avibactam.
  2. 2. The beta-lactamase inhibitor in Emblaveo.
  3. 4. The approval of Emblaveo was supported by the Phase 3 ___ study.
  4. 7. The month that Emblaveo was FDA-approved.
  5. 8. One challenge of treating complicated intra-abdominal infections is achieving ___ control.